Additionally, HSOS reduces hypercoagulability and inflammation in tumor blood by lowering levels of tissue factor (TF), fibrinogen (FIB), and interleukin-6 (IL-6), while inhibiting angiogenesis-related factors such as CD44, metalloproteinase-2 (MMP-2), and vascular endothelial growth factor (VEGF) 33. The gene discussed is VEGFA; the disease is neoplasm.